Christoph Mann

702 total citations
10 papers, 53 citations indexed

About

Christoph Mann is a scholar working on Hematology, Molecular Biology and Surgery. According to data from OpenAlex, Christoph Mann has authored 10 papers receiving a total of 53 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 5 papers in Molecular Biology and 2 papers in Surgery. Recurrent topics in Christoph Mann's work include Multiple Myeloma Research and Treatments (8 papers), Cancer Mechanisms and Therapy (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). Christoph Mann is often cited by papers focused on Multiple Myeloma Research and Treatments (8 papers), Cancer Mechanisms and Therapy (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). Christoph Mann collaborates with scholars based in Germany, Austria and Switzerland. Christoph Mann's co-authors include Anne Marie Asemissen, Ellen Wollmer, Elisabeth Mack, Hartmut Goldschmidt, Jörg Hoffmann, Cornelia Brendel, Britta Besemer, Raphael Lutz, Andreas Neubauer and Carsten Bokemeyer and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Chemistry and Laboratory Medicine (CCLM) and Annals of Hematology.

In The Last Decade

Christoph Mann

7 papers receiving 53 citations

Peers

Christoph Mann
Raphael Lutz Germany
Titouan Cazaubiel France
Marta Reinoso Segura Spain
Eneida Pardo United States
Sandra Martínez-Martín Spain
Camille Montersino France
Marianne Huben United States
Matthew R. Hart United States
Paulina Richter‐Pechańska Germany
Samuel M. Rubinstein United States
Raphael Lutz Germany
Christoph Mann
Citations per year, relative to Christoph Mann Christoph Mann (= 1×) peers Raphael Lutz

Countries citing papers authored by Christoph Mann

Since Specialization
Citations

This map shows the geographic impact of Christoph Mann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christoph Mann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christoph Mann more than expected).

Fields of papers citing papers by Christoph Mann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christoph Mann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christoph Mann. The network helps show where Christoph Mann may publish in the future.

Co-authorship network of co-authors of Christoph Mann

This figure shows the co-authorship network connecting the top 25 collaborators of Christoph Mann. A scholar is included among the top collaborators of Christoph Mann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christoph Mann. Christoph Mann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Trenker, Corinna, et al.. (2025). Presentation of extramedullary myeloma manifestations on B-mode (B-US) and contrast-enhanced ultrasound (CEUS). Journal of Ultrasonography. 25(101). 20250015–20250015. 1 indexed citations
2.
Mann, Christoph, et al.. (2025). Beyond the Hydrashift assay: the utility of isoelectric focusing for therapeutic antibody and paraprotein detection. Clinical Chemistry and Laboratory Medicine (CCLM). 63(9). 1766–1772.
3.
4.
Mack, Elisabeth, Ellen Wollmer, Christoph Mann, et al.. (2022). Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells. Annals of Hematology. 101(4). 811–824. 16 indexed citations
5.
Kriegsmann, Katharina, Calin Manta, Ricarda Schwab, et al.. (2022). Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM. Blood Advances. 7(3). 379–383.
6.
Weisel, Katja, Anne Marie Asemissen, Britta Besemer, et al.. (2020). Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial.. Journal of Clinical Oncology. 38(15_suppl). 8508–8508. 15 indexed citations
7.
Mann, Christoph, Brajesh P. Kaistha, Michael Kacik, Thorsten Stiewe, & Joachim Hoyer. (2019). Downregulation of miR-503 in Activated Kidney Fibroblasts Disinhibits KCNN4 in an <b><i>in Vitro</i></b> Model of Kidney Fibrosis. Kidney & Blood Pressure Research. 44(1). 113–122. 6 indexed citations
8.
Sohlbach, Kristina, Stephan Metzelder, Ellen Wollmer, et al.. (2019). Outcome of non-mold effective anti-fungal prophylaxis in patients at high-risk for invasive fungal infections after allogenic stem cell transplantation. Leukemia & lymphoma. 60(8). 2056–2061. 3 indexed citations
9.
Weisel, Katja, Anne Marie Asemissen, Aneta Schieferdecker, et al.. (2019). Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd) in front-line treatment of high-risk Multiple Myeloma: Results of the Safety Run-In cohort in the phase II, multicenter GMMG-CONCEPT trial. Clinical Lymphoma Myeloma & Leukemia. 19(10). e17–e17. 10 indexed citations
10.
Asemissen, Anne Marie, Stella E. Autenrieth, Cécile Gouttefangeas, et al.. (2019). Prospective monitoring of immune signatures in newly diagnosed high risk multiple myeloma patients under treatment with Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd): First results of the GMMG-CONCEPT trial. Clinical Lymphoma Myeloma & Leukemia. 19(10). e141–e142. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raphael Lutz Breakdown of academic impact, for papers by Titouan Cazaubiel Breakdown of academic impact, for papers by Marta Reinoso Segura Breakdown of academic impact, for papers by Eneida Pardo Breakdown of academic impact, for papers by Sandra Martínez-Martín Breakdown of academic impact, for papers by Camille Montersino Breakdown of academic impact, for papers by Marianne Huben Breakdown of academic impact, for papers by Matthew R. Hart Breakdown of academic impact, for papers by Paulina Richter‐Pechańska Breakdown of academic impact, for papers by Samuel M. Rubinstein
Rankless by CCL
2026